Jeremy Bender - 23 Apr 2026 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Reporting relationship
CHIEF EXECUTIVE OFFICER, Director
Issuer ticker
DAWN
Reported as of
23 Apr 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Apr 2026, 16:40:56 UTC
Prior SEC filing
27 Feb 2026
Next SEC filing
08 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Charles N. York II, as Attorney-in-Fact

Key filing fact

Jeremy Bender filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 23 Apr 2026.

Key facts

  • This page summarizes Jeremy Bender's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
  • 17 reported transactions and 10 derivative rows are listed below.
  • Accepted by SEC: 23 Apr 2026, 16:40.

Change

  • Previous filing in this sequence was filed on 27 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001863107 Primary reporting owner

Bender Jeremy

Relationship
CHIEF EXECUTIVE OFFICER, Director
Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Signature date
23 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-204,643
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Footnotes
F1, F2
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-20,204
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F3
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-300,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F4
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-147,702
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F5
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-18,197
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F6
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-300,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F7
DAWN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-808,285
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
See footnote
Footnotes
F1, F2, F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-1,463,134
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,463,134
Exercise price
$8.99
Footnotes
F9, F10
DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-397,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
397,000
Exercise price
$8.99
Footnotes
F10, F11
DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-244,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
244,000
Exercise price
$8.99
Footnotes
F10, F12
DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-286,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
286,000
Exercise price
$8.99
Footnotes
F10, F13
DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-286,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
286,000
Exercise price
$8.99
Footnotes
F10, F14
DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Disposed to Issuer

Transaction value
Shares
-355,000
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
355,000
Exercise price
$11.16
Footnotes
F10, F15
DAWN transaction Derivative

Restricted Stock Unit (RSU)

Disposed to Issuer

Transaction value
Shares
-14,250
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,250
Exercise price
Footnotes
F10, F16, F17, F18
DAWN transaction Derivative

Restricted Stock Unit (RSU)

Disposed to Issuer

Transaction value
Shares
-81,816
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
81,816
Exercise price
Footnotes
F10, F16, F17, F18
DAWN transaction Derivative

Restricted Stock Unit (RSU)

Disposed to Issuer

Transaction value
Shares
-128,565
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
128,565
Exercise price
Footnotes
F10, F16, F17, F18
DAWN transaction Derivative

Restricted Stock Unit (RSU)

Disposed to Issuer

Transaction value
Shares
-222,188
Change %
-100%
Price
Shares after
0
Date
23 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
222,188
Exercise price
Footnotes
F10, F16, F17, F18
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jeremy Bender is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 18 footnotes

Footnote F1

On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

Footnote F2

Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

Footnote F3

Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.

Footnote F4

Represents shares held by the Jeremy Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person is trustee.

Footnote F5

Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.

Footnote F6

Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.

Footnote F7

Represents shares held by the Melissa Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person's spouse is trustee.

Footnote F8

Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees.

Footnote F9

The options are fully vested.

Footnote F10

Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

Footnote F11

The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F12

The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F13

The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F14

The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F15

The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F16

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F17

The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F18

RSUs do not expire; they either vest or are canceled prior to the vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .